Our recent studies have shown that ZDHHC2 promotes sunitinib resistance in renal cell carcinoma by increasing the membrane localization of acylglycerol kinase (AGK).[35] Similarly, we demonstrated that ZDHHC2 promotes enzalutamide resistance in prostate cancer cells, and mechanistically, we discovered that ZDHHC2 inhibits ferroptosis in prostate cancer cells. This evidence concerns the gene AGK and hereditary clear cell renal cell carcinoma.